Marijuana Dependence Clinical Trial
Official title:
Treatment of Marijuana Withdrawal Syndrome Using Escitalopram and Cognitive-Behavior Therapy- a Double-Blind Placebo-Controlled Study
Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. We predict that combined pharmacological treatment and cognitive-behavior therapy will help patients to abstain from using using marijuana and it will alleviate their marijuana withdrawal symptoms.
Recent studies have established the reliability, validity and time course of the cannabis
withdrawal syndrome characterized by symptoms of anxiety, irritability, negative mood,
physical symptoms and decreased appetite. This study will investigate the effects of
combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the
symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. 40
patients will be blindly randomized to either active or placebo escitalopram 10mg/day, for
12 weeks followed bt 12 weeks of follow-up.
Inclusion criteria include:
- Men and women age 20-45
- DSM-IV diagnosis of THC dependence.
Exclusion criteria include:
- Dependence on other drugs or alcohol
- Bipolar Disorder or Schizophrenia, Major depression, suicidal ideation psychotic
symptoms or violent thoughts
- Current treatment with anti-depressant medication
- Neurological disease
- Physical illness (hypothyroidism, severe anemia, renal failure)
- Past severe effects of SSRIs.
Outcome measures include:
- urine THC analysis every two weeks
- questionnaires assessing addiction severity index
- depression and anxiety.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00875836 -
Buspirone Treatment for Marijuana Dependence
|
Phase 4 | |
Completed |
NCT00893269 -
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep
|
Phase 1 | |
Completed |
NCT00490269 -
Ph1 Marinol Interaction Study - Part 2 - 1
|
Phase 1 | |
Completed |
NCT02579421 -
Hormones and Reduction in Co-users of Marijuana and Nicotine
|
N/A | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT00373295 -
Effect of Baclofen on Marijuana Withdrawal and Relapse
|
Phase 2 | |
Active, not recruiting |
NCT01827332 -
Effect of Oxytocin on Craving and Therapy Response
|
N/A | |
Completed |
NCT01335789 -
Effect of Oxytocin on Stress in Marijuana Users
|
N/A | |
Terminated |
NCT00438139 -
Ph1 Marinol Interaction Study - Part 1 - 1
|
Phase 1 | |
Completed |
NCT02955329 -
Vaping THC From Electronic Cigarettes
|
Phase 3 | |
Completed |
NCT02439814 -
Pregnenolone and Marijuana Dependence
|
Phase 2 | |
Completed |
NCT01347762 -
Nabilone for Cannabis Dependence: A Pilot Study
|
Phase 2/Phase 3 | |
Completed |
NCT01039415 -
Attempts to Stop/Reduce Marijuana Among Dependent Users
|
N/A | |
Completed |
NCT00270803 -
The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana
|
N/A | |
Completed |
NCT01020019 -
Combined Pharmacotherapy for Cannabis Dependency
|
Phase 2/Phase 3 | |
Completed |
NCT02030665 -
Marijuana Treatment Project 4
|
N/A | |
Completed |
NCT00107588 -
Marijuana Treatment Project - 3
|
N/A | |
Completed |
NCT02011516 -
Baclofen Effects on Marijuana Dependence
|
Phase 2 | |
Completed |
NCT00350649 -
Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management
|
Phase 2 | |
Completed |
NCT00374127 -
Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper
|
Phase 2 |